JOINT VENTURE AGREEMENT FOR LOCAL PRODUCTION OF VACCINES
Act · Health
An Act establishes a joint venture for local vaccine production in Nigeria, involving partnerships with the Federal Government. It targets the Federal Ministry of Health and pharmaceutical companies to facilitate technology transfer and manufacturing facilities. This aims to reduce dependency on imported vaccines and enhance immunization coverage.
What Is This Policy?
A joint venture agreement between the Federal Government and partners for the local production of vaccines in Nigeria, reducing dependency on imported vaccines.
Who Does It Target?
Federal Ministry of Health, pharmaceutical companies, public health agencies, healthcare workers, and all Nigerians requiring vaccination.
What Does It Aim to Achieve?
Achieve local vaccine production capacity, reduce vaccine importation costs, ensure vaccine security, and improve immunization coverage.
Key Features
Local Production: Establishes vaccine manufacturing facilities in Nigeria. Technology Transfer: Involves transfer of vaccine production technology to Nigeria. Supply Security: Reduces dependency on imported vaccines. Cost Reduction: Aims to lower vaccine costs through local production.
Current Status
Rollout Stage: Active with ongoing development. Coverage: Nationwide vaccine supply. Funding: Federal government, joint venture partners, and development partners.
How to Access
Vaccines produced locally are distributed through the national immunization programme. Access vaccines through primary healthcare centres Follow the national immunization schedule
Impact & Metrics
Expected to improve vaccine availability and immunization coverage across Nigeria.
Official Resources
Website: health.gov.ng Contact: Federal Ministry of Health, Abuja
Legal Framework
Operates under the National Health Act 2014, the National Agency for Food and Drug Administration and Control Act 1993, and the National Biotechnology Policy. Draws on the Vaccines Manufacturing policy framework, the National Immunization Policy, and Nigeria's bilateral and multilateral agreements with vaccine development partners and the African Union.